L1CAM and ovarian carcinoma: Moreover, in 2012 Schäfer et al. demonstrated in an in vivo murine model that L1CAM could be a suitable target for treatment of ovarian cancers when L1CAM-specific humanized antibodies were combined with conventional chemotherapy, e.g. paclitaxel.